Stay updated with breaking news from Published March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2-...
Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.
Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.